Long-term open-label study to assess the safety, tolerability and efficacy of GIVINOSTAT in patients with Duchenne muscular dystrophy who have previously been treated in the study with GIVINOSTAT.

Trial Profile

Long-term open-label study to assess the safety, tolerability and efficacy of GIVINOSTAT in patients with Duchenne muscular dystrophy who have previously been treated in the study with GIVINOSTAT.

Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 02 Feb 2018

At a glance

  • Drugs Givinostat (Primary)
  • Indications Duchenne muscular dystrophy
  • Focus Adverse reactions; Registrational
  • Sponsors Italfarmaco
  • Most Recent Events

    • 26 Dec 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top